Health Care & Life Sciences » Biotechnology | Ligand Pharmaceuticals Inc.

Ligand Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Ligand Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
iShares Core S&P Small Cap ETF
1,177,193
5.58%
333
0.64%
09/06/2018
Vanguard Total Stock Market Index Fund
515,571
2.44%
506
0.02%
07/31/2018
Vanguard Small Cap Index Fund
509,005
2.41%
6,810
0.14%
07/31/2018
iShares Russell 2000 ETF
439,965
2.09%
-234
0.24%
09/06/2018
SPDR S&P Biotech ETF
373,050
1.77%
960
1.66%
09/06/2018
iShares S&P Small Cap 600 Growth ETF
365,774
1.73%
525
1.3%
09/06/2018
Conestoga Small Cap Fund
364,625
1.73%
7,300
3.87%
07/31/2018
Janus Triton Fund
359,172
1.7%
0
0.8%
06/30/2018
Glenmede Small Cap Equity Fund
312,403
1.48%
-47,087
2.02%
04/30/2018
Vanguard Small Cap Growth Index Fund
290,809
1.38%
4,358
0.28%
07/31/2018

About Ligand Pharmaceuticals

View Profile
Address
3911 Sorrento Valley Boulevard
San Diego California 92121
United States
Employees -
Website http://www.ligand.com
Updated 07/08/2019
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.